ClinicalTrials.gg
RecruitingNCT07868926Updated Oct 30, 2026

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

A Phase 1 interventional study of 14C-VX-407 in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 1 site in United States. Open to male participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 30, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Planned enrollment
59th of 63
8 · median 48
Started
2026
with 4 others
Phase 1
10 of 85
2 open now
Primary completion
2026-12
later than 3 of 24 live
Registered
85th of 85
by date
Lead sponsor
6 of 85
Vertex Pharmaceuticals Incorporated

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 59th largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 3 of the 24 other live ones, and was the 85th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 19 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.

Read the detailed description

The purpose of the study is to evaluate the pharmacokinetics of VX-407 following a single oral dose. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
  • A total body weight of more than (>) 50 kg
  • Participants must have regular bowel movements (i.e., average of more than or equal to (>=) 1 and less than or equal to (\<=)3 stools per day)

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption, distribution, metabolism, or excretion
  • Exposure to any nonenvironmental radiation (e.g., diagnostic medical imaging or occupational exposure) within 12 months before study drug administration
  • Participation in more than 1 radiolabeled study (if the previous study's radiation exposure is unknown) or participation in more than 3 radiolabeled studies (if the previous studies' radiation exposure is known) in the 12 months before dosing or if the annual whole-body radiation exposure from all previous studies (including this dosing) is more than the FDA-allowed maximum whole body radiation exposure of 5000 mrem

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    14C-VX-407

    Participants will receive a single oral dose of 14C-VX-407 after an overnight fast of at least 8 hours.

    Drug: 14C-VX-407

Interventions

  • Drug14C-VX-407

    Solution for Oral Administration.

06

What researchers measure

Primary outcomes

  1. Amount of Radioactivity Excreted (Ae) of 14C-VX-407 Total Radioactivity (TRA) in Urine, and Feces

    Time frame: From Day -1 up to Day 30

  2. Terminal Phase Rate Constant (λz) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  3. Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  4. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  5. Apparent Clearance (CL/F) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  6. Renal Clearance (CLr) of VX-407

    Time frame: From Day -1 up to Day 30

  7. Maximum Observed Plasma Concentration (Cmax) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  8. Time for VX-407 to Reach Maximum Concentration (Tmax) of VX-407 in Plasma and Urine

    Time frame: From Day 1 up to Day 30

  9. Fraction (percent) of Dose Excreted Unchanged in Urine of VX-407 (fe)

    Time frame: From Day -1 up to Day 30

  10. Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-407 in Plasma

    Time frame: From Day 1 up to Day 30

  11. Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

  12. AUC0-tlast of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

  13. AUC0-inf of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

  14. CL/F of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

  15. Cmax of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

  16. Fraction (percent) of Dose Excreted Unchanged in Urine of TRA

    Time frame: From Day -1 up to Day 30

  17. Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma

    Time frame: From Day 1 up to Day 30

Secondary outcomes

  1. Metabolite Profiling and Identification in Plasma, Urine, and Feces

    Time frame: From Day 1 up to Day 30

  2. Terminal Phase Rate Constant (λz) of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  3. AUC0-tlast of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  4. AUC0-inf of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  5. Cmax of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  6. Tmax of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  7. Apparent Volume of Distribution (Based on the Terminal Phase) of VX-407 Metabolites in Plasma

    Time frame: From Day 1 up to Day 30

  8. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 41

07

Study locations

1 of 1 sites recruiting
  • Celerion - Lincoln
    Lincoln, Nebraska 68502, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Dec 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartActual
Oct 16, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
1 site added — first site in United States
Show site
  • Celerion - Lincoln · Lincoln, United States
Oct 30, 2026
Start date
Oct 19, 2026→Oct 16, 2026 (actual)
Oct 30, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 2 updates
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Celerion - Lincoln · Lincoln, United States
    Start date Oct 19, 2026→Oct 16, 2026 (now actual)
  2. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868926
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Oct 16, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 30, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion